Integra LifeSciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides 2021 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Integra LifeSciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides 2021 Financial Guidance
February 18, 2021 4:21 PM EST
Truist Securities analyst Kaila Krum raised the price target on Integra LifeSciences (NASDAQ: IART) to $75.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "Integra announced Q4 2020 results, with revenue of $389 million coming in at the high end of its preliminary range that... More
February 18, 2021 6:26 AM EST
Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.84, $0.11 better than the analyst estimate of $0.73. Revenue for the quarter came in at $388.6 million versus the consensus estimate of $388.58 million.
Fourth Quarter 2020
Reported revenues were $388.6 million, representing a decrease of 1.6% on a reported basis and a decrease of 1.5% on an organic basis compared to the fourth quarter 2019.Fourth quarter revenues increased 5.0% compared to the third quarter of 2020.GAAP earnings per diluted share were $1.09, compared to $0.18 in the fourth quarter 2019.Adjusted earnings per diluted share were $0.84, compared to...
More
